Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eduardo Vilar

Showing results (1-10 of 228) with videos related to

Pageof 23
Sort By:
Alimentary Pharmacology & Therapeutics|November 10, 2022
Editorial: food insecurity, diet quality, racial and ethnic disparities in non-alcoholic fatty liver diseaseEduardo Vilar-Gomez
The Lancet. Gastroenterology & Hepatology|July 7, 2023
NAFLD and liver-related events: does type 2 diabetes have a key role?Eduardo Vilar-Gomez
Nature|June 29, 2012
Cancer: Pinprick diagnosticsEduardo Vilar, Josep Tabernero
Cancer Discovery|March 5, 2013
Molecular dissection of microsatellite instable colorectal cancerEduardo Vilar, Josep Tabernero
Journal of Hepatology|November 21, 2017
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkersEduardo Vilar-Gomez, Naga Chalasani
Hepatology (Baltimore, Md.)|March 12, 2019
ReplyEduardo Vilar-Gomez, Naga Chalasani
Alimentary Pharmacology & Therapeutics|September 19, 2019
Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' replyEduardo Vilar-Gomez, Naga Chalasani
Alimentary Pharmacology & Therapeutics|July 17, 2025
Editorial: ABID-LSM-A Promising Model for Predicting Decompensation Risk in MASLD CirrhosisEduardo Vilar-Gomez, Samer Gawrieh
Alimentary Pharmacology & Therapeutics|September 19, 2019
Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Authors' replyEduardo Vilar-Gomez, Naga Chalasani
JAMA Oncology|December 16, 2016
Universal Genetic Testing for Younger Patients With Colorectal CancerEduardo Vilar, Elena M Stoffel
Pageof 23

Showing results (1-10 of 228) with videos related to

Sort By:
Pageof 23
Alimentary Pharmacology & Therapeutics|November 10, 2022
Editorial: food insecurity, diet quality, racial and ethnic disparities in non-alcoholic fatty liver diseaseEduardo Vilar-Gomez
The Lancet. Gastroenterology & Hepatology|July 7, 2023
NAFLD and liver-related events: does type 2 diabetes have a key role?Eduardo Vilar-Gomez
Nature|June 29, 2012
Cancer: Pinprick diagnosticsEduardo Vilar, Josep Tabernero
Cancer Discovery|March 5, 2013
Molecular dissection of microsatellite instable colorectal cancerEduardo Vilar, Josep Tabernero
Journal of Hepatology|November 21, 2017
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkersEduardo Vilar-Gomez, Naga Chalasani
Hepatology (Baltimore, Md.)|March 12, 2019
ReplyEduardo Vilar-Gomez, Naga Chalasani
Alimentary Pharmacology & Therapeutics|September 19, 2019
Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' replyEduardo Vilar-Gomez, Naga Chalasani
Alimentary Pharmacology & Therapeutics|July 17, 2025
Editorial: ABID-LSM-A Promising Model for Predicting Decompensation Risk in MASLD CirrhosisEduardo Vilar-Gomez, Samer Gawrieh
Alimentary Pharmacology & Therapeutics|September 19, 2019
Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Authors' replyEduardo Vilar-Gomez, Naga Chalasani
JAMA Oncology|December 16, 2016
Universal Genetic Testing for Younger Patients With Colorectal CancerEduardo Vilar, Elena M Stoffel
Pageof 23